SCIEGEN PHARMACEUTICALS H-1B Visa Sponsorship & Salary Data

The median H-1B salary at SCIEGEN PHARMACEUTICALS is $81,432, based on 70 certified filings from FY 2021 to FY 2026. This is 32% lower than the national H-1B median salary of $120,000. Compensation at SCIEGEN PHARMACEUTICALS reflects their market positioning, with entry-level roles starting around $66,800 and senior positions reaching $102,000 or higher. These figures represent base salaries in LCA filings and may not include bonuses, equity grants, or other compensation common at large employers.

Salaries at SCIEGEN PHARMACEUTICALS range from $61,300 at the 10th percentile to $102,000 at the 90th percentile, showing a $40,700 spread across experience levels and roles. The 25th percentile is $66,800 and the 75th percentile is $91,400.

Yes, SCIEGEN PHARMACEUTICALS actively sponsors H-1B visas in FY 2026. In the most recent fiscal year (FY 2026), SCIEGEN PHARMACEUTICALS filed 10 H-1B labor condition applications with 10 certified and 0 denied, at a median salary of $91,951. Across FY 2021–2026, they have filed 70 total H-1B applications with 70 certified and a 0% lifetime denial rate, demonstrating ongoing commitment to hiring international talent. SCIEGEN PHARMACEUTICALS sponsors positions across multiple job categories and locations, making them a viable option for professionals seeking H-1B visa sponsorship.

In the most recent fiscal year (FY 2026), SCIEGEN PHARMACEUTICALS filed 10 H-1B applications, with 10 certified and 0 denied. Over 5 years of data, SCIEGEN PHARMACEUTICALS has consistently demonstrated commitment to H-1B sponsorship.

Note: These are Labor Condition Applications (LCAs) filed with the Department of Labor, which is a prerequisite for H-1B petitions. The actual number of H-1B petitions filed with USCIS may differ.

SCIEGEN PHARMACEUTICALS's LCA (Labor Condition Application) denial rate is 0%, with 0 out of 70 applications denied across all years. This translates to a 100.0% certification rate, which indicates how successfully the company prepares and files H-1B applications. A lower denial rate suggests better compliance with Department of Labor requirements, proper wage documentation, and accurate job classification. Prospective H-1B applicants should consider this approval rate alongside other factors like salary, job role, and location when evaluating SCIEGEN PHARMACEUTICALS as a potential H-1B sponsor.

This is an excellent approval rate, indicating SCIEGEN PHARMACEUTICALS has strong H-1B sponsorship practices and typically meets DOL requirements. Applicants can feel confident in the company's H-1B track record.

SCIEGEN PHARMACEUTICALS sponsors H-1B visas for various specialty occupation positions requiring at least a bachelor's degree. Based on 70 certified filings, the most commonly sponsored job titles reflect the company's primary business functions and talent needs. These positions typically require specialized knowledge in fields like technology, engineering, finance, or scientific research. Understanding which roles SCIEGEN PHARMACEUTICALS most frequently sponsors can help job seekers target their applications effectively.

Most common H-1B job titles at SCIEGEN PHARMACEUTICALS:

The most frequently sponsored role is Qc Chemist with 16 filings at a median salary of $70,600. This is followed by QA Chemist (15 filings) and Equipment Engineer.

SCIEGEN PHARMACEUTICALS's H-1B positions are distributed across multiple U.S. locations, with concentration in major metropolitan areas and tech hubs. Geographic distribution often reflects company office locations, client sites, and regional market demands. Location significantly impacts H-1B salary due to varying cost of living and local wage requirements. Understanding where SCIEGEN PHARMACEUTICALS sponsors H-1B workers can help candidates target specific offices and negotiate appropriate compensation for each market.

Top SCIEGEN PHARMACEUTICALS H-1B locations:

The largest H-1B hub for SCIEGEN PHARMACEUTICALS is Hauppauge, NY with 70 filings at a median salary of $81,432.

SCIEGEN PHARMACEUTICALS's median H-1B salary has increased by +37% from FY 2021 ($67,080) to FY 2026 ($91,951). Tracking salary trends over time reveals how SCIEGEN PHARMACEUTICALS adjusts compensation to remain competitive in the H-1B labor market. Salary growth typically reflects inflation adjustments, increased demand for specialized skills, and evolving prevailing wage requirements. These historical trends can help applicants understand future salary expectations and negotiate appropriately when considering H-1B opportunities at SCIEGEN PHARMACEUTICALS.

Year-by-year breakdown:

• FY 2021: $67,080 (26 certified)
• FY 2022: $75,000 (12 certified)
• FY 2024: $88,240 (14 certified)
• FY 2025: $95,493 (8 certified)
• FY 2026: $91,951 (10 certified)

This 37% growth reflects strong compensation adjustments at SCIEGEN PHARMACEUTICALS, keeping pace with market demands for H-1B talent.

SCIEGEN PHARMACEUTICALS primarily files H-1B applications at Wage Level I, accounting for 50% of their filings. DOL wage levels range from Level I (entry-level, 17th percentile of local wages) to Level IV (expert, 67th percentile). Wage level determines both salary requirements and, under recent H-1B rules, lottery selection priority. Higher wage levels receive preference in the H-1B lottery, making SCIEGEN PHARMACEUTICALS's wage level distribution an important factor for prospective applicants assessing their chances of H-1B selection.

SCIEGEN PHARMACEUTICALS has a mix of entry-level (Level I) and experienced (Level II+) H-1B positions. This reflects a range of roles from junior to senior.

SCIEGEN PHARMACEUTICALS's median H-1B salary of $81,432 is 32% lower than the national H-1B median of $120,000 across all employers and industries. This comparison provides context for evaluating SCIEGEN PHARMACEUTICALS's competitiveness in attracting H-1B talent. Keep in mind that industry, location, and job function significantly impact salary levels. Tech companies and financial institutions typically offer higher H-1B salaries than other sectors, while salaries in major metros like San Francisco and New York exceed those in smaller markets. Compare SCIEGEN PHARMACEUTICALS's offerings with similar companies in your field for a more accurate assessment.

SCIEGEN PHARMACEUTICALS's H-1B salaries are below the national median, though this may vary significantly by role, experience level, and location. Consider researching specific positions for more accurate compensation expectations.

Recent H-1B rule changes have increased filing fees and introduced wage-level prioritization in the lottery. SCIEGEN PHARMACEUTICALS files 50% of positions at Level I, which may face more lottery competition under wage-level prioritization rules.

With 70 certified filings, SCIEGEN PHARMACEUTICALS invests significantly in H-1B sponsorship. The company's 0% denial rate suggests strong compliance with H-1B requirements and documentation standards.

Note: H-1B regulations are subject to change. Fees shown are estimates based on 2024 USCIS fee schedules. Actual costs may vary based on company size, premium processing, and future rule changes.